Background-Genome-wide association studies enabled us to discover a large number of variants and genomic loci contributing to cardiovascular and metabolic disorders. However, because the vast majority of the identified variants are thought to merely be proxies for other functional variants, the causal mechanisms remain to be elucidated. We hypothesized that the part of the functional variants involved in deregulating cardiometabolic genes is located in microRNA (miRNA)binding sites. Methods and Results-Using the largest genome-wide association studies available on glycemic indices, lipid traits, anthropometric measures, blood pressure, coronary artery diseases, and type 2 diabetes mellitus, we identified 11 067 variants that are associated with cardiometabolic phenotypes. Of these, 230 variants are located within miRNA-binding sites in the 3′-untranslated region of 155 cardiometabolic genes. Thirty-seven of 230 variants were found to fulfill our predefined criteria for being functional in their genomic loci. Ten variants were subsequently selected for experimental validation based on genome-wide association studies results, expression quantitative trait loci (eQTL) analyses, and coexpression of their host genes and regulatory miRNAs in relevant tissues. Luciferase reporter assays revealed an allele-specific regulation of genes hosting the variants by miRNAs. These cotransfection experiments showed that rs174545 (FADS1:miR-181a-2), rs1059611 (LPL:miR-136), rs13702 (LPL:miR-410), rs1046875 (FN3KRP:miR-34a), rs7956 (MKRN2:miR-154), rs3217992 (CDKN2B:miR-138-2-3p), and rs11735092 (HSD17B13:miR-375) decrease or abrogate miRNA-dependent regulation of the genes. Conversely, 2 variants, rs6857 (PVRL2:miR-320e) and rs907091 (IKZF3:miR-326), were shown to enhance the activity of miRNAs on their host genes. Conclusions-We provide evidence for a model in which polymorphisms in miRNA-binding sites can both positively and negatively affect miRNA-mediated regulation of cardiometabolic genes. (Circ Cardiovasc Genet. 2015;8:473-486.
C ardiometabolic disorders including cardiovascular disease (CVD) and several metabolic abnormalities that increase CVD risk are major worldwide health problem. 1 Over the past few decades, remarkable progress has been made in identifying the genes that are responsible for cardiometabolic disorders. The recent development of novel techniques, including genomewide association studies (GWAS), has led to the identification of a large number of single-nucleotide polymorphisms (SNPs) and specific genomic loci that contribute to the induction of different cardiometabolic traits and diseases. [2] [3] [4] A large proportion of the identified SNPs associated with cardiometabolic disorders are located in noncoding regions of the genome that are responsible for fine-tuning gene expression regulation. 2, 3, 5, 6 Many studies to date have focused on annotating GWAS hits and functional variants that are located in the 3′-untranslated regions (3′UTR). 6, 7 Increasing evidence suggests that the genes 3′UTRs contain regulatory elements that play important roles in gene expression. 7, 8 Genetic variations in these regions may affect gene expression through different mechanisms. This includes altering recognition sites for microRNAs (miRNA), RNA-binding proteins, and the polyadenylation machinery. 8, 9 miRNAs play an important role in modulating the susceptibility to and onset of complex disorders, therefore, research has focused on identifying polymorphisms in miRNA-binding sites. 10, 11 miRNAs are small noncoding RNAs, consisting of 20 to 24 nucleotides, that regulate numerous biological processes by post-transcriptional regulation of gene expression. 12 miR-NAs can repress translation and, to a lesser extent, decrease the stability of mRNAs by interacting with the complementary sequences in the 3′UTR of target genes. 12 The seed sequence, which has been defined as nucleotides 2 to 8 of a miRNA, is essential for target recognition and regulation. 12 Genetic variation in either a miRNA's seed sequence or the complementary sequence in the 3′UTR of target gene could adversely affect target recognition, resulting in aberrant gene expression. 10, 13 Both computational and experimental studies have revealed that variants in miRNA-binding sites can modulate the risk of disease induction by disrupting the original recognition site or creating an alternative binding site for miRNAs. [14] [15] [16] [17] miRNAs have been shown to regulate the expression of genes that are involved in induction of CVD and regulation of various metabolic processes, such as insulin production, glucose homeostasis, lipid metabolism, and obesity. 18, 19 However, to date, only a few pathogenic miRNA-related variants have been identified that affect the regulation of genes associated with cardiometabolic phenotypes. 10, 11, 13 In this study, we hypothesized that genetic variants within miRNA-binding sites could constitute part of the functional SNPs involved in deregulating cardiometabolic genes. To test this hypothesis, we have investigated whether variants that were previously identified by GWAS of cardiometabolic phenotypes reside in miRNA-binding sites. In addition, we linked several publicly available data sets and tools, such as GWAS findings, eQTL data, miRNA, and gene expression profiles, and combined them with experimental studies to identify functional variants that can alter miRNAmediated regulation of their host cardiometabolic genes.
Methods

Retrieval of Cardiometabolic-Associated Variants
We used data from the recent GWAS meta-analyses on 17 cardiometabolic traits and diseases to identify genetic variants that are associated with cardiometabolic phenotypes. To increase our statistical power and robustness, we used the largest GWAS available on these phenotypes. The GWAS summary statistics of glycemic homeostasis indices (fasting glucose, serum glucose after 2 hours, fasting insulin, fasting proinsulin, hemoglobin A1c, homeostatic model assessment-B, and homeostatic model assessment-insulin resistance) from the Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC), [20] [21] [22] [23] [24] lipid phenotypes (plasma concentrations of total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglyceride) from the Global Lipid Genetics Consortium (GLGC), 2 anthropometric measures (body mass index and waist to hip ratio) from the Genetic Investigation of ANthropometric Traits (GIANT) consortium, 25, 26 systolic and diastolic blood pressure from the Global Blood Pressure Genetics (Global BPgen) consortium, 27 coronary artery disease from the Coronary ARtery DIsease Genome wide Replication and Meta-analysis plus The Coronary Artery Disease Genetics (CARDIoGRAMplusC4D) consortium 4 and type 2 diabetes mellitus from the DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) consortium 3 were analyzed. A description of the GWAS meta-analyses on these cardiometabolic phenotypes, the consortia responsible for these analyses, and the number of SNPs associated with each trait or disease is provided in Table 1 .
In total 11 067 unique SNPs (in 629 genomic loci) were found to be associated with 17 cardiometabolic phenotypes at a genomewide statistical significance level (P value <5×10 -8 ). We calculated the number of independent SNPs using linkage disequilibrium (LD)based SNP pruning in PLINK tool-set with R 2 >0.8 (http://pngu.mgh. harvard.edu/≈purcell/plink/). On this basis, 2369 of these SNPs were independent.
Genetic Polymorphisms in miRNA-Binding Sites
Multiple target prediction algorithms, including the TargetScan (http://TargetScan.org/), miRTarBase (http://mirtarbase.mbc.nctu. edu.tw/) and miRecords (http://miRecords.umn.edu/ miRecords) databases, were used to identify genes that are predicted to be targeted by human miRNAs. We subsequently determined that all variants were located in miRNA-binding sites in the 3′UTR of these genes using the following online databases: PolymiRTS, 16 Patrocles, 17 and miRdSNP. 28 By adding the data from these databases together, we made a comprehensive data set of all variants located in miRNAbinding sites. Because GWAS meta-analyses on cardiometabolic phenotypes have been performed using HapMap imputed data, we focused on those variants that were present in the list of 2.5 million HapMap SNPs, release 22 (n=23 650). No copy number variants were studied because the HapMap project does not include copy number variants. The approach we used to determine which variants were identified as cardiometabolic-associated SNPs and were localized in miRNA-binding sites is visualized in Figure 1 .
eQTLs Survey
Functional polymorphisms in miRNA-binding sites are expected to alter the expression levels of their host genes by affecting the activity of miRNAs on the target transcripts. We examined cis-eQTL meta-analysis data that were generated from 8086 peripheral blood samples (http://genenetwork.nl/bloodeqtlbrowser/) to determine the association between identified cardiometabolic SNPs in miRNAbinding sites and the expression levels of their host transcripts. This particular cis-eQTL data set was used because of its large sample size and power. In addition, 2 other online web browsers, including Genevar (http://www.sanger .ac.uk/resources/software/genevar) and GTEx (http://www.broadinstitute.org/gtex/), were searched for cis-eQTL data in relevant tissues, such as adipose tissue, liver, left ventricle, and muscle skeletal. The Genevar platform provides information on eQTL in adipose, skin, and lymphoblastoid cell lines (LCLs) collected from 856 healthy female twins of the Multiple Tissue Human Expression Resource (MuTHER) Study. 29 To illustrate the strength of the correlation between alleles and gene expression levels, we used the eQTL plots were generated by the Genevar web tool with a subset of the MuTHER Study (n=160), in which the expression of target genes in both adipose tissue and blood was correlated to individual genotypes based on the Spearman's rank correlation coefficient. SNPs determined to exhibit a cis-effect on the expression levels of their host transcripts (increase or decrease) were selected for further analyses.
Expression of the Identified Genes and miRNAs in Cardiometabolic Tissues
A functional prerequisite for miRNA-dependent gene regulation is that a miRNA and its target mRNAs are coexpressed in the same tissue. 9 To determine whether the identified genes hosting the SNPs and their miRNAs express in relevant cardiovascular tissues, multiple web tools were used. We examined expression of the identified target genes across adipose tissue, liver, heart, skeletal muscle, and blood using the Human BodyMap 2.0 data (http://www.ensembl. info/blog/2011/05/24/human-bodymap-2-0-data-from-illumina/). To scan miRNA expression in cardiometabolic tissues, we used the mi-miRNA (http://mimirna. centenary.org.au), PhenomiR (http://mips. helmholtz-muenchen.de/phenomir), and HMDD (http://cmbi.bjmu. edu.cn/hmdd) online databases. We subsequently used Pubmed to search through literature for those miRNAs that were not included in the above-mentioned databases.
Furthermore, to determine whether the interactions of the highlighted miRNAs and their target genes have previously been validated using functional experiments, multiple online databases, including miRTarBase, Tarbase (http://www.diana.pcbi.upenn.edu/tarbase), and miRwalk (http://www.umm.uni-heidelberg.de/apps/zmf/ mirwalk), were searched. Additional information on miRNA sequences, host genes, miRNA families and clusters, and miRNA conservation between species was obtained from the miRBase (release 20) and TargetScan (release 6.2) databases.
Selection of Variants and Related miRNAs for Functional Analysis
Specific criteria have been suggested to establish whether variants in miRNA-binding sites are functional. 9 These criteria include an established association between the variant and the phenotype, the expression of the miRNA and its target gene in a relevant tissue, and an allele-specific expression of the gene hosting the variant. We used the above-mentioned criteria to prioritize the SNPs and experimentally examine the impact of a number of them on the miRNA and target mRNA interactions. Ten variants were subsequently selected for the validation phase based on the GWAS results (the significance of association), the eQTL analysis (effect and P value in a relevant tissue), and the evidence for coexpression of their host genes with regulatory miR-NAs in relevant cardiometabolic tissues. In addition, when a gene is targeted by >1 related miRNA in our collection, the experiments were performed using a miRNA that is highly conserved, as the conserved miRNAs across mammals and primates are considered of functional significance. 30
3′UTR Luciferase Reporter Assays
Luciferase reporter assays were performed to first validate the selected genes as miRNA targets and then to investigate the effect of target site polymorphisms on the interaction between miRNAs and target genes. The 3′UTR sequences of genes were amplified from genomic DNA of subjects homozygous for either major or minor alleles using a forward primer containing a XhoI restriction site and a reverse primer containing a EcoRI restriction site. The amplified 3′UTR fragments were subsequently cloned into the pGL3 luciferase reporter vector downstream of the Luciferase open reading frame (Promega). Similarly, mature miRNA sequences were amplified using a forward primer containing a XhoI restriction site and a reverse primer containing a EcoRI restriction site. The amplified miRNA sequences were then cloned into the MSCV-BC (Murine Stem Cell Virus-Bar Coded) vector. 31 Sanger sequencing was performed to verify the DNA sequence of the plasmids. HEK293 cells, plated into 12-well plates (Costar), were cotransfected with a 3′UTR luciferase reporter construct and a miRNA or empty vector control. Luciferase values were normalized to the Renilla luciferase value to correct for differences in transfection efficiencies. All experiments were performed in triplicate.
LD Structure Analysis of the Validated SNPs
The list of cardiometabolic SNPs that were experimentally validated to have functional impact on the miRNA activity were submitted to the SNAP web tool (http://www.broad institute.org/mpg/snap/id) using R 2 threshold >0.8, limit distance 500 kb, and population panel CEU (Northern and Western European Ancestry) to retrieve their proxy SNPs in the HapMap project. To examine the functional potential of the SNPs, we used the HaploReg database (http://www.broad institute.org/mammals/haploreg/) which predict the effect of a SNP on protein structure, gene regulation, and splicing using data from the ENCODE project.
Results
Cardiometabolic-Associated Variants That Are Located in miRNA-Binding Sites
A total of 11 067 unique SNPs in 629 genomic loci were identified to be associated with 17 cardiometabolic phenotypes at a statistically significant level (P value <5×10 -8 ). Table 1 shows a description of the cardiometabolic phenotypes, the number of variants associated with each phenotype, and the consortia that generated these data. The proportion of these cardiometabolic-associated SNPs in different parts of the genes is shown in Figure 2 . Searching through literature and various online databases enabled us to identify 409 853 variants that are located in putative miRNA-binding sites within the 3′UTRs of genes. Subsequent analysis of the 2.5 million HapMap SNPs showed that 23 650 of these miRNA-binding site variants were present in this list, indicating that ≈1% of imputed SNPs from the HapMap project (release 22) are likely to reside in miRNA-binding sites. We identified 16 370 independent SNPs in the collection of 23 650 miRNA-binding site SNPs that were present in the HapMap, using the LD-based SNP pruning function implemented in PLINK (R 2 >0.8). It is estimated that the number of independent common SNPs in the human genome are 1 million. 32 This indicates that ≈1.7% of imputed independent SNPs from the HapMap are predicted to be in miRNA-binding sites. Here, we found 230 SNPs (157 independent SNPs) of 11 067 SNPs (2369 independent SNPs) associated with cardiometabolic phenotypes to be located in miRNA-binding sites. Therefore, the frequency of cardiometabolic GWAS findings in miRNA-binding sites is ≈2× larger than other parts of the genome (P value <0.05 as determined by Fisher exact test). If we consider the independent SNPs, this frequency is ≈4× higher than the expected number in other parts of the genome.
The 230 identified SNPs represent 2% and 24%, respectively, of all GWAS identified SNPs and loci associated with cardiometabolic phenotypes. As shown in Table S1 in the Data Supplement, some of these SNPs were found to be associated with >1 phenotype. We generated regional association plots of 155 loci that harbored these 230 SNPs using the locuszoom web tool (https://statgen.sph.umich.edu/locuszoom/). 33 Many of these variants appeared to be either sentinel SNPs which showed the strongest association with phenotype in the given genomic region or were one of the SNPs with the strongest associations. Table II in the Data Supplement shows a list of miRNAs that, based on their binding sites, are likely to be affected by these 230 SNPs.
miRNA-Binding Site Variants With Cis-Effect on Their Host Genes Expression
Cis-eQTL data were used to determine the correlation between the 230 SNPs and the expression levels of their host transcripts in tissues relevant for cardiometabolic phenotypes, such as blood and adipose tissue. From 230 variants, 57 SNPs (located in 45 genes) were significantly associated with altered expression levels of their host transcripts ( Table 2 ). More information about the observed GWAS associations of these 57 SNPs with cardiometabolic phenotypes is depicted in Table III in the Data Supplement. A significant association was detected between the variants located in the 3′UTRs of FN3KRP, FADS1, CPEB4, LPL, MKRN2, GRINA, MMAB, KIAA0892, and NT5C2 and their transcripts expression levels in multiple tissues, suggesting the functional significance of these variants on the related gene expression in cardiometabolic disorders. We could generate eQTL plots for some of these variants using the Genevar web tool to illustrate the correlations between individuals carrying different genotypes, the eQTL plots of the 8 candidate SNPs were shown in Figure 3 and plots of other SNPs are shown in Figure I in the Data Supplement.
Expression of the Identified Genes and miRNAs in Relevant Cardiometabolic Tissues
Coexpression of a miRNA and its target genes in the same tissue is a prerequisite for miRNA-mediated regulation of target genes. We searched multiple online databases and literature to find evidence for coexpression of 45 genes that harbored the 57 identified variants with their regulatory miRNAs in cardiometabolic tissues. Table IV in the Data Supplement shows the genes expression across different tissues, indicating that almost all of the studied genes are expressed in cardiovascular tissues. In addition, expression of their related miRNAs in adipose tissue, liver, heart, pancreas, and skeletal muscle was investigated. These analyses revealed that 29 of 45 genes (hosting 37 of the variants) are expressed with their predicted miRNAs in relevant cardiometabolic tissues (Table 3 ).
Functional Impact of the Candidate Variants on the miRNA-mRNA Interactions
Luciferase reporter assays were performed to first validate the putative interactions between genes hosting the SNPs and specified miRNAs and to second determine the effects of SNPs on the expression levels of their host transcripts. Ten of the 37 identified SNPs were selected for functional validation based on their GWAS results, eQTL analysis, and expression of their related genes and miRNAs in cardiometabolic tissues ( Table VII in the Data Supplement. In addition, mature miRNA sequences were amplified and cloned into the MSCV-BC vector. Cotransfection of luciferase constructs with the major alleles for the 8 variants predicted to disrupt miRNA-mRNA interactions with miRNAs, resulted in a significant decrease in luciferase activity in 7 variants (rs174545:G, rs1059611:T, rs13702:T, rs11735092:A, rs7956:T, rs3217992:G, and rs1046875:T). This experiment confirmed that miRNAs can regulate the 3′UTRs harboring the wild-type alleles. In addition, the cotransfection experiments revealed that the miRNAmediated inhibition of FADS1, LPL, HSD17B13, MKRN2, CDKN2B, and FN3KRP is significantly reduced (P value <0.05 as determined by the Mann-Whitney test) when the 3′UTRs contain the mutant alleles (Figure 4 ). No significant differences were observed between the luciferase activities of MMAB constructs containing either major or minor alleles (rs877710) in presence of miR-593-5p, indicating that this particular variant does not affect the miRNA-mediated regulation of MMAB at mRNA level. Similar experiments were performed to identify the role of other 2 variants in the miRNA-mRNA interactions. A dose-dependent effect was observed of miR-320e and miR-326 on the expression levels of PVRL2 and IKZF3, respectively, in presence of the minor alleles ( Figure II in the Data Supplement). The presence of a minor allele significantly increased the interaction between miR-320e and the 3′UTR of PVRL2 as was visualized by a decreased luciferase activity (from 90% to 50%, in 1/2 miRNA concentration). Similarly, although cotransfection of the major allele construct of IKZF3 (rs907091) with miR-326, resulted in a nonsignificant reduction in luciferase activity, cotransfection of the minor allele further reduced luciferase activity (from 95% to 60%, in 1/4 miRNA concentration). These findings indicate that the mutant alleles in PVRL2 and IKZF3 enable miR-320e and miR-326, respectively, to more efficiently regulate the expression of their host transcripts ( Figure 5 ).
Evaluation of the LD Structure of the Loci Containing the Experimentally Validated SNPs
Proxy SNPs (R 2 >0.8 and MAF>0.10) in strong LD with the 9 selected variants were extracted, and their predicted effects on protein structure and gene regulation using the HaploReg database were investigated. Detailed information of these proxies and their predicted functions were provided in Table  VIII in the Data Supplement. This data further showed that the 9 studied variants are likely to be functional variants in their genomic regions.
Discussion
In this study, we performed a genome-wide scan to identify functional variants that may associate with cardiometabolic phenotypes through affecting miRNA-mediated regulation of cardiometabolic genes. We annotated 230 SNPs have been identified by GWAS for cardiometabolic traits/diseases to miRNAbinding sites. We determined that 37 of these SNPs (representing 29 genes) fulfill our predefined criteria for being functional in their genomic loci. Using luciferase reporter assay for 10 prioritized variants, we showed that rs174545 (FADS1), rs1059611 and rs13702 (LPL), rs1046875 (FN3KRP), rs7956 (MKRN2), rs3217992 (CDKN2B) and rs11735092 (HSD17B13) decrease miRNA-dependent regulation of their corresponding transcripts. Conversely, rs6857 (PVRL2) and rs907091 (IKZF3) were shown to enhance the activity of miRNAs on their host transcripts. Our results strongly suggest that allele-specific miRNA regulation of genes by variants in miRNA-binding sites could serves as a functional mechanism underlying GWAS findings. Although GWAS have led to the discovery of thousands of variants that seem to contribute to cardiometabolic disorders, most of the identified variants are located in noncoding regions of the genome and their functionality remains to be investigated. To determine the most likely functional candidate SNPs in noncoding regions, novel approaches are required. A potential mechanism for GWAS identified variants is to influence gene expression by affecting the interactions between miRNAs and target mRNAs. Because the seed sequences in miRNAs have to be perfectly complementary to binding sites for target recognition, genetic variations in the miRNA seed regions or their binding sites can lead to increased disease susceptibility. 8, 10, 13, 15 From the time that an association between a mutation in the binding site of miR-189 and the pathogenesis of Tourette's syndrome has been demonstrated, 14 a considerable level of variation in miRNA target sites has been reported. To date, catalogues and online databases for this variability have been developed which provide a valuable resource for epidemiological studies. 16, 17, 28 However, these databases are mainly based on bioinformatics approaches and include only a limited number of functional annotations. 
Expression of miRNAs in Cardiometabolic Tissues
In this study, we linked several publicly available data sets and tools and combined them with experimental studies to identify the most likely functional variants that are located in the 3′UTR of cardiometabolic genes. We identified 230 cardiometabolic risk SNPs that were predicted to either abolish the existing miRNA-binding sites or create new putative binding sites. This number is higher than the expected by chance and may suggest an enrichment of GWAS findings in miRNA-binding sites. In addition, because miRNAs are highly conserved, and negative selection is stronger on their putative binding sites than on other conserved sequence motifs in the 3′UTR of genes, 34 the vast majority of miRNA-binding site variants are rare and absent in the GWAS data imputed from the HapMap project. Therefore, a higher enrichment level of cardiometabolic-associated variants in miRNA-binding sites can be expected if dense genotyping methods (GWAS from 1000 genome imputed data) or sequencing will implement in association studies.
Specific criteria have previously been suggested to establish whether variants in miRNA-binding sites are functional, including an established association between the variant and the phenotype, the expression of the host gene and regulatory miRNA in a relevant tissue and an allele-specific expression of the host gene. 9 We determined 37 from the 230 SNPs that were found to be associated with cardiometabolic phenotypes and located in miRNA-binding sites fulfill all the above-mentioned criteria for being functional. These 37 SNPs are the most likely functional candidate variants in their genomic loci and propose for experimental studies. These results further indicate that ≈16% of SNPs that are located in miRNA-binding sites may be functional.
Ten SNPs were selected for functional validation. Our results, first demonstrate the interaction between studied miR-NAs and the 3′UTRs of FADS1 (miR-181a-2), LPL (miR-136 and miR-410), HSD17B13 (miR-375), MKRN2 (miR-154), CDKN2B (miR-138-2-3p), and FN3KRP (miR-34a), resulting in reduced gene expression. We subsequently showed that the miRNA-dependent regulation of these genes is significantly decreased when mutant alleles are present in their 3′UTRs. Among all, the rs1173092 mutant allele completely abrogates the miR-375-binding site and results in the normal expression of HSD17B13. Other variants partially disrupt their related miRNA-binding sites. This variability in disrupting the miRNA-binding sites may be fully explained by compensation of the miRNA binding to its target by match sequences outside the seed that is called compensatory 3′ end pairing. 35 In addition, the position of mutated nucleotide in a miRNA target site is important. Sometimes such SNP could completely disrupt the target site and strongly affect the binding of miRNA to the target mRNA, and sometimes just leads to the activity of miRNA on the target transcript with lower affinity.
Both FADS1 and its specified miRNA, miR-181a-2-3p, have been shown to be involved in regulation of lipid metabolism. 36, 37 In this study, we showed that the minor allele of rs174545 in the 3′UTR of FADS1 disrupts the binding site of miR-181a-2-3p. In addition, eQTL analysis revealed that carriers of this particular mutant allele display an elevated FADS1 expression. Thus, an allele-specific miR-181a-2-3pmediated regulation of FADS1 expression may partly explain the observed GWAS association with lipid traits. LPL, another gene shown to be regulated by miRNAs exhibits a strong association with the levels of serum triglyceride and cholesterol and is implicated in the pathogenesis of CVD. 2, 38 Its regulatory miRNAs, miR-410 and miR-136-5p, are highly expressed in adipocytes and are known regulators of adipogenesis. 10, 39 In this study, we determined that the rs13702 and rs1059611 mutant alleles can modulate, respectively, the interaction of miR-410 and miR-136-5p with the LPL 3′UTR. Similarly, Richardson et al 10 have demonstrated that the interaction between miR-410 and LPL is disrupted by variant rs13702. Although the importance of rs13702 in disruption of miRNA-mediated regulation of LPL expression has previously been shown, our results revealed that miRNA-mediated regulation of LPL can also be abrogated by variant rs1059611. Dysregulation of LPL by these miRNA-binding site SNPs may be one of the functional explanation for the identified GWAS association between LPL and the level of serum cholesterol. Figure 5 . Experimental validation of 2 candidate single-nucleotide polymorphisms (SNPs) that were predicted to increase the interactions between miRNAs and their host genes. These variants significantly enhance miRNA-mediated regulation of their host genes, PVRL2 cotransfected with 50% of miR-320e normal concentration, and IKZF3 cotransfected with 25% of miR-326 normal concentration. Data were depicted as fold reduction compared with empty vector (EV), wild-type (Wt) allele controls. n=3 replicates for each condition. Error bars represent SE of the mean.
Our results demonstrated that, similar to FADS1 and LPL, mutant alleles significantly reduce the interactions between HSD17B13 (rs11735092) and MKRN2 (rs7956) and their regulatory miRNAs, miR-375 and miR-154-5p. Aberrant regulation of these genes by miR-375 and miR-154-5p could be a reason behind the associations between HSD17B13 and triglycerides and between MKRN2 and total cholesterol levels. In addition, although HSD17B13 has been shown to be expressed in adipose tissue, miR-375 is known to be involved in regulation of glucose and lipid metabolism. 40 The expression patterns of both MKRN2 and miR-154-5p in adipocytes were also in accordance with our expectations. 41 CDKN2B has been shown to be associated with coronary artery disease, myocardial infarction, and type 2 diabetes mellitus. 4, 42 GWA and experimental studies have revealed that the rs3217992 minor allele is protective against incident coronary artery disease. 4,43 miR-138-2-3p has been reported to be required for normal cardiac development and function. 44 Furthermore, Horswell et al 45 have previously been exhibited that this miRNA has an effect on both CDKNB2 mRNA and protein levels. In this study, we showed that the rs3217992 minor allele disrupts miR-138-2-3p-mediated regulation of CDKN2B, thereby increasing the transcript levels of the gene. These findings may indicate that allelic-specific regulation of CDKN2B by miR-138-2-3p as a potential explanation for the association between CDKN2B (rs3217992) and the susceptibility to coronary artery disease. Finally, we revealed that although miR-34a-5p can interact with the wild type 3′UTR of FN3KRP, this interaction was significantly reduced by the mutant allele (rs1046875). MiR-34a-5p is highly expressed in liver and plays important regulatory role in pancreatic development and insulin secretion. 46 The disruption of the interaction between miR-34a and FN3KRP by rs1046857 may provide a reason, at least in part, for the association of FN3KRP with hemoglobin A1c. 23 Although a large number of variants in 3′UTRs have been demonstrated to disrupt the existing miRNA-binding sites, only a few studies have provided experimental evidence showing variants that improve the original recognition sites or create novel-binding sites. 47 In this study, we investigated the functionality of 2 variants that were predicted to enhance the binding of miR-320e and miR-326 to PVRL2 and IKZF3, respectively. Previous GWAS on lipid traits have revealed associations between PVRL2 and lipid traits and between IKZF3 and high-density lipoprotein-cholesterol. Furthermore, both miR-320e and miR-326 are highly expressed in adipose tissue and pancreas. 40, 48, 49 Luciferase experiments revealed that the mutant alleles rs6857 and rs907091 enhanced the binding of miR-320e to PVRL2 and miR-326 to IKZF3, respectively. It has previously been shown that target gene regulation requires a specific concentration of miRNAs. 50 This explains why, in our experiments, a dose-dependent effect could be observed. These results demonstrate an allelespecific regulation of PVRL2 and IKZF3 by miR-320e and miR-326 that may be the underlying cause of their GWAS associations with lipid traits.
A limitation of our study needs to be addressed. We tried to provide functional evidence for the miRNA-target gene interactions and the impact of miRNA-binding site SNPs on these interactions. It should be noted that miRNA activities on the transcripts of interest are largely dependent on the cell type and expression levels of both miRNA and their competing targets. Therefore, it is optimal to do quantitative measure of coexpression for the identified genes and related miRNAs in target tissues (such as liver, skeletal muscle, and adipose tissue). In addition, the chain of evidences would be more complete if we examine the influences of SNPs on post-transcriptional regulation of the miRNA targets. Unfortunately, we did not have a model system available to test expression levels of the protein products of the identified miRNA targets in the right cellular context in vivo. However, to gain more insights in the function of the SNPs, we used the wellaccepted in vitro luciferase reporter assays in combination with eQTL data, and miRNA and gene expression profiles that provide strong support for the functionality of these 3′UTR polymorphisms.
In conclusion, we have demonstrated that SNPs located in 3′UTRs and miRNA-binding sites can affect miRNAmediated regulation of genes involved in cardiometabolic disorders. These findings improve our understanding of the roles of miRNAs in the pathophysiology of CVD and metabolic syndromes. Our findings may be of clinical importance because they indicate that specific miRNAs can modify gene expression profiles and affect cardiometabolic phenotypes. This study shows that a multidisciplinary approach, including bioinformatics, epidemiology, and molecular biology, can be used to identify the most likely functional candidate variants in specific genomic regions. This approach could be applied to a wide range of phenotypes and may contribute to improving the annotation of GWAS findings.
